By Nigam Arora & Dr. Natasha Arora
Lordstone Motors (RIDE) has been a troubled EV maker. If it was not for the momo and meme crowds, the stock would have fallen to under $1. The stock is trading at $6.44 as of this writing in the premarket. RIDE has appointed Daniel Ninivaggi as Chief Executive. Ninivaggi is highly connected to financial sources. He is the former CEO of IEP. It is not known if Carl Icahn will make an investment in RIDE.
This is suitable only for super-aggressive investors as RIDE has fallen behind and it may be difficult to catch up. The buy zone is $5. to $6.78. The stop zone is $4.43 to $4.73. The first target zone is $7.68 to $8.37. The second target zone is $8.88 to $11. The maximum recommended quantity is 25% or less based on risk preference of full core position size.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES,
TAKE A FREE TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
